SCHEMBL221917

SCHEMBL221917

CCCCCC1C(=O)NC(=O)N1CCCCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.41
TSHR P16473 1/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 2/20 0.39
TP53 P04637 1/20 0.39
MMP1 P03956 2/20 0.39
MMP3 P08254 2/20 0.39
MMP9 P14780 2/20 0.39
PRKCD Q05655 4/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
ABL1 P00519 2/20 0.37
RIN1 Q13671 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11396127 0.87 TSHR (0.58) TSHRHIF1AHSD17B10LMNAMEN1
SCHEMBL10714123 0.81 PRKCD (0.42) GBA1LMNAGAATP53PRKCD
SCHEMBL27082407 0.81 GAA (0.46) GBA1TSHRHIF1AHSD17B10LMNA
SCHEMBL1363122 0.79 MMP1 (0.45) GBA1TSHRHIF1AHSD17B10LMNA
SCHEMBL11093126 0.78 TSHR (0.55) TSHRHIF1AHSD17B10LMNAMEN1
SCHEMBL11093813 0.78 KMT2A (0.50) TSHRHIF1AHSD17B10LMNAMEN1
SCHEMBL10633237 0.76 GBA1 (0.46) GBA1TSHRGAATP53PRKCD
SCHEMBL11864710 0.75 ALDH1A1 (0.37) PRKCDKDM4EMEN1ALDH1A1MAPT
SCHEMBL6235119 0.75 GBA1 (0.53) GBA1GAATP53PRKCDKDM4E
SCHEMBL6231243 0.75 GBA1 (0.53) GBA1GAATP53PRKCDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197701-A1 ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK APPLIED BIOLOGY, INC. 2024-06-20 US claimed
US-20220186227-A1 Therapeutic Targets for Oncogenic KRAS-Dependent Cancers UNIVERSITY OF MASSACHUSETTS 2022-06-16 US claimed
EP-3946629-A1 THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS University Of Massachusetts (US) 2022-02-09 EP claimed
WO-2020198488-A1 THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS UNIVERSITY OF MASSACHUSETTS (US) 2020-10-01 WO claimed
CN-108658869-A Compound with anti-tumor activity and preparation method thereof and the purposes in pharmacy 复旦大学 2018-10-16 CN claimed
EP-3329775-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS Medivation Prostate Therapeutics LLC (US) 2018-06-06 EP claimed
US-9174943-B2 Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds MEDIVATION PROSTATE THERAPEUTICS, INC. (US) 2015-11-03 US claimed
CN-103108549-B Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds MEDIVATION PROSTATE THERAPEUTICS, INC. (US) 2015-09-09 CN claimed
WO-2015042170-A1 COMPOSITIONS AND USES OF COMBINATIONS OF DIM-RELATED INDOLES AND SELECTED ANTI-ANDROGEN COMPOUNDS WAYNE STATE UNIVERSITY (US) 2015-03-26 WO claimed
CN-104341396-A Diaryl hydantoin derivative, as well as preparation method, medicine composition and application thereof SHANGHAI PHARMACEUTICALS HOLDING CO LTD 2015-02-11 CN claimed
EP-2646553-A1 COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS Santaris Pharma A/S (DK) 2013-10-09 EP claimed
US-20130190507-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS MEDIVATION PROSTATE THERAPEUTICS LLC 2013-07-25 US claimed
CN-103108549-A Method for synthesizing diarylthiohydantoin and diarylhydantoin compounds MEDIVATION PROSTATE THERAPEUTICS INC 2013-05-15 CN claimed
EP-2538785-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS Medivation Prostate Therapeutics, Inc. (US) 2013-01-02 EP claimed
WO-2012065051-A1 COMPOSITIONS AND METHODS FOR TREATING ANDROGEN RECEPTOR DEPENDENT DISORDERS INCLUDING CANCERS ENZON PHARMACEUTICALS, INC. (US) 2012-05-18 WO claimed
WO-2011106570-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS MEDIVATION PROSTATE THERAPEUTICS, INC. (US) 2011-09-01 WO claimed
US-20240197701-A1 ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK APPLIED BIOLOGY, INC. 2024-06-20 US disclosed
US-20240197701-A1 ANDROGEN RECEPTOR INHIBITION TO TREAT SEPSIS AND SHOCK APPLIED BIOLOGY, INC. 2024-06-20 US disclosed
WO-2006124118-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-11-23 WO disclosed
EP-0383092-A2 Chromogenic merocyanine enzyme substrates Bayer Corporation (US) 1990-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190507-A1 PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS BPHL, PTMS, DHPS GBA1 4309/4885TSHR 3067/4885HIF1A 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.